Urinary Tubular Biomarkers for Chronic Kidney Disease
ConditionChronic Kidney Disease Stage 3
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorErasmus Medical Center
About this trial
Currently used tests for chronic kidney injury only assess the function of one part of the kidney: the filter called the glomerulus. The other part, called the tubule, is disregarded. Based on many previous studies, the investigators have good reason to assume that a better prediction of the course of chronic kidney disease by testing tubular function will be possible. This is important, for example, when patients need to be treated with kidney-protecting drugs.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Chronic kidney disease stage 3 (eGFR 30-59ml/min)
Disqualifiers
Active glomerulonephritis treated with immunosuppression
Kidney transplant recipient
Current treatment with chemo- or immunotherapy for malignancy
Trial population
Adult patients (≤18 years) with CKD stage 3, treated at the Internal Medicine outpatient department of the Erasmus MC university hospital (convenience sampling).
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Urinary tubular test panel
Diagnostic testThe urinary tubular test panel will be applied to urine samples that are collected as part of the routine outpatient follow-up. Its predictive power for CKD progression will be assessed. The results of the tubular test panel will not influence the treatment of the patients. They will remain under standard outpatient treatment throughout the study.
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
CKD Progression
Rate of participants that reach the composite of 30% reduction in estimated glomerular filtration rate (CKD-EPI creatinine-based) and/or the initiation of kidney replacement therapy (dialysis or kidney transplantation)
Time frame
3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov